Patrys has today released its Annual Report for the 2022-23 Financial Year (FY23).
Highlights include:
- Successful completion of the PAT-DX1 engineering run
- New data demonstrating PAT-DX1/radiation combination improves brain cancer survival in a pre-clinical model
- PAT-DX1 GLP toxicology reports received
- New PAT-DX3 data demonstrating synthetic lethality
- Completion of the master cell bank and integration run for PAT-DX3
- The appointment of Dr. Charmaine Gittleson as Chairman